1-3 of 3
Elber S. Camacho, MD
Close
Sort by
Journal Articles

A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma

William I. Bensinger, MD, Robert Vescio, MD, Cristina Gasparetto, MD, Elber S. Camacho, MD, Rajneesh Nath, MD, Christina L. Gomes, MD, David D. Smith, PhD, Jatin J. Shah, Brian G. M. Durie, MD
Journal: Blood
Blood (2014) 124 (21): 4739.
https://doi.org/10.1182/blood.V124.21.4739.4739
Published: 2014
Journal Articles

A Phase II Study of Bortezomib (Velcade ® ), Cyclophosphamide (Cytoxan ® ), Thalidomide (Thalomid ® ) and Dexamethasone as First-Line Therapy for Multiple Myeloma

William Bensinger, Sundar Jagannath, MD, Robert Vescio, MD, Elber S. Camacho, MD, Jeffrey Lee Wolf, David H Irwin, MD, Gerardo Capo, III, MD, Marti McKinley, Phyllis Potts, David H. Vesole, MD, PhD, Amitabha Mazumder, MD, Dixie-Lee Esseltine, MD, Pamela Becker, John Crowley, PhD, Brian GM Durie, MD
Journal: Blood
Blood (2008) 112 (11): 94.
https://doi.org/10.1182/blood.V112.11.94.94
Published: 2008
Journal Articles

Bendamustine HCl (TREANDA TM ) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01).

Jonathan W. Friedberg, MD, Philip Cohen, MD, Bruce D. Cheson, MD, K. Sue Robinson, MD, Andres Forero-Torres, MD, Luis Fayad, MD, Ann S. La Casce, MD, Alberto Bessudo, MD, Elber S. Camacho, MD, Michael E. Williams, MD, Richard H. van der Jagt, MD, Jennifer Oliver, MD, Ely Benaim, MD
Journal: Blood
Blood (2005) 106 (11): 229.
https://doi.org/10.1182/blood.V106.11.229.229
Published: 2005